-
CPEX Pharmaceuticals Advises Stockholders to Take No Action in Response to Mangrove Partners' Proposal
Tuesday, March 15, 2011 - 8:35am | 77CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today confirmed that it has received an unsolicited, non-binding letter from Mangrove Partners regarding a potential alternative transaction involving a recapitalization of CPEX. CPEX has also said that its Board of Directors will review the terms of the...
-
Citi Comments On FRX Core Product And Pricing Trends
Tuesday, March 15, 2011 - 8:29am | 314In its core product and pricing trends for the week ending 3-4-11, Citi is focusing on the following Forest Laboratories, Inc. (NYSE: FRX) products: Lexapro: “~$2.82B Annual Run Rate Implied by 4-Week Average TRx's vs. Our FY'11E US Sales of $2.28B,” Citi writes. “Lexapro posted wkly NRx/TRx of 232...
-
Citi Comments On ENDP Core Product And Pricing Trends
Tuesday, March 15, 2011 - 8:24am | 329In its core product and pricing trends for the week ending 3-4-11, Citi is focusing on the following Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) products: Lidoderm: “~$970M Annual Run Rate Implied by 4-Wk Avg. TRx's vs. Our 2011E Sales of ~$800M (+2%),” Citi writes. “4Q10 growth was +1% vs....
-
Progenics Pharmaceuticals Reports Q4 EPs of $(0.57) vs. $(0.57)
Tuesday, March 15, 2011 - 8:13am | 120Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter ended December 31, 2010. Net loss for the fourth quarter was $18.8 million or $0.57, basic and diluted, per share, compared to $0.6 million or $0.02, basic and diluted, per share in the...
-
Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods
Tuesday, March 15, 2011 - 8:10am | 93Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection (CDI) treatment with fidaxomicin. The patent, which is eligible for listing in the U.S...
-
Piper Jaffray Comments On Simcere Pharmaceutical Following Earnings Report
Tuesday, March 15, 2011 - 8:03am | 162Simcere Pharmaceutical's (NYSE: SCR) 4Q10 earnings results disappointed Piper Jaffray on margin leverage and new products sales trends, and argue against the notion of significant margin leverage and accelerating new product sales on the stock. Specifically, operating margin declined during the...
-
Piper Jaffray Raises PT On Simcere Pharmaceutical Group To $10
Tuesday, March 15, 2011 - 6:39am | 30Piper Jaffray has raised the price target on Simcere Pharmaceutical Group (NYSE: SCR) from $8.40 to $10 and maintains its Neutral rating.
-
JP Morgan Upgrades Shire To Overweight
Tuesday, March 15, 2011 - 5:42am | 46Analysts at JP Morgan upgrade Shire Plc (NASDAQ: SHPGY) from “neutral” to “overweight.” SHPGY shares fell 0.19% to close at $87.25 yesterday. More Analyst Ratings here
-
Earnings Scheduled For March 15 (AIR, DSW, SSRX, CRZO, BPZ, ESLT, RUE, BWS, INFI, ALXA, BWEN, CHDX, ATPG)
Tuesday, March 15, 2011 - 3:02am | 369AAR Corp (NYSE: AIR) is projected to report its Q3 EPS at $0.42 on revenue of $447.38 million. DSW Inc (NYSE: DSW) is estimated to report its Q4 earnings at $0.44 per share on revenue of $462.95 million. 3SBio Inc (NASDAQ: SSRX) is expected to post its Q4 EPS at $0.06 on revenue of $14.35 million...
-
Mike Khouw's Pfizer (PFE) Trade
Monday, March 14, 2011 - 10:00pm | 153Tim Anderson, a Sanford Bernstein analyst, suggested today that Pfizer Inc. (NYSE: PFE) might be considering a spin off of its lower margin businesses. CNBC Options Action's, Mike Khouw talked on the show about an options strategy in Pfizer Inc. (PFE) that could help you to profit on this comment...
-
VIX Remains Contained 03-14-2011
Monday, March 14, 2011 - 7:01pm | 769Cusick's Corner Volatility, the VIX, remains contained, 21.13, and the market bounced off the lows, S&P June Futures 1990. The bulls garnered enough control to quell some of the fears that have recently entered the markets. With that being said, all eyes will be on the FOMC meeting tomorrow at...
-
Impact Difficult to Price Into Market 03-14-2011
Monday, March 14, 2011 - 3:06pm | 822Cusick's Corner The market is down, but the total impact of Japan is far from over or able to be priced into the market. The market could look to establish a base right around the 1275 level on the S&Ps. What is known is that is volatility is on the move in both names related to Japan and the...
-
Standpoint Research Downgrades Pfizer to Hold
Monday, March 14, 2011 - 10:26am | 20Standpoint Research downgrades Pfizer (NYSE: PFE) from Buy to Hold.
-
Pfizer Hits 52-Week High Today (PFE)
Monday, March 14, 2011 - 9:56am | 33Pfizer (NYSE: PFE) hit its 52-week high today. At the time of posting, shares of PFE were trading at $19.99, up 2.67% from Friday's close.
-
Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals
Monday, March 14, 2011 - 8:39am | 139Mangrove Partners, owners of 149,373 shares representing approximately 5.71% of the outstanding shares of CPEX Pharmaceuticals, Inc. (Nasdaq: CPEX), today announced that it has sent a term sheet for a fully-financed dividend recapitalization to CPEX's Board of Directors to be implemented through a...